ILMN Earnings

ILMN reported its earnings on 2026-02-05, showcasing a revenue of 1.16B against an estimate of 1.16B, resulting in a -0.09% surprise. The EPS was 1.35, surpassing the expected 1.26 by 7.14% . The stock experienced a -10.4% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following ILMN's earnings announcement on 2026-02-05, the stock price moved by -10.40% on the day of the release. Over the subsequent five days, it saw a % change. Historically, ILMN's stock price tends to shift by an average of +0.67% in the 10 days leading up to earnings and -3.78% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate ILMN’s annual revenue to reach 1.06B, while the EPS is projected at 1.11. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 0.02% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ILMN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 0.02% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ILMN's stock price typically moves by +0.67% in the 10 days before its earnings and -3.78% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.11 and revenue of 1.06B.

The earnings call summary and Q&A indicate strong financial performance with 16% EPS growth and improved margins. Despite challenges in Greater China, the overall growth outlook is optimistic, especially with high single-digit revenue growth and strategic transitions like NovaSeq X. The Q&A reveals confidence in achieving long-term targets and strong demand in clinical markets. The lack of detailed M&A criteria and cautious guidance for 2026 are minor concerns, but the positive aspects outweigh these, suggesting a positive stock price movement.